CHEST 2026 Abstracts Link GLP-1 Drugs to Better Sleep Apnea Outcomes

This article is based on that report.

Obstructive sleep apnea is a condition in which the airway collapses during sleep. Managed Healthcare Executive notes that obesity is a major contributor. It also notes that in late 2024 the FDA approved Zepbound (tirzepatide) as a treatment for severe apnea. The outlet describes the wider field as unsettled, with many open questions.

The largest finding in the report concerns acute respiratory failure, a rare but dire complication of sleep apnea. Researchers led by Shubham Gupta, M.D., used the TriNetX Research Network database. According to the report, they compared about 470,000 patients with obesity and sleep apnea who had been treated with a GLP-1 against nearly 1.5 million who had not.

At one year, acute respiratory failure occurred in 1.4% of GLP-1 users and 2.3% of nonusers, which the report describes as a 40% lower risk. At five years, the rates were 3.5% and 5.5%, a 36% lower risk. Gupta and colleagues caution against drawing cause-and-effect conclusions from retrospective research like this, according to the report.

A second abstract looked at CPAP, the mask-and-air-pump treatment many people find hard to stick with. Bibek Timilsina, M.D., and colleagues also used TriNetX. According to Managed Healthcare Executive, starting a GLP-1 was associated with higher CPAP adherence: 36% versus 28.9%. The report says the team used equipment claims as a stand-in for actual use rather than direct measures. It calls the work a first-take study that no one considers the final word.

A third abstract, by David Savage-Lobeck, M.D., and colleagues, is a systematic review of randomized trials of semaglutide and tirzepatide. As reported, the drugs were associated with lower apnea-hypopnea index, a measure of how often breathing is disrupted, and a "profound" drop in hypoxic burden, a measure of low blood oxygen during sleep. Weight loss tracked closely with the apnea improvement. But it accounted for only 54% of the drop in systolic blood pressure and 42% of the improvement in an inflammation marker, per the report.

What does this mean for people living with sleep apnea? The report suggests GLP-1s did not push people away from CPAP in this data. The review abstract's authors wrote that GLP-1s "should be considered primary cardioprotective therapy" in what they call "metabolic-OSA," particularly for patients with high hypoxic burden or CPAP, a phrase the coverage quotes in truncated form. That is a recommendation about protecting the heart, not about treating apnea itself, and it is the researchers' interpretation. The findings do not show that GLP-1s replace CPAP.

Questions remain. A separate review in the Journal of Clinical Sleep Medicine, led by Christopher N. Schmickl, M.D., Ph.D., M.P.H., cites research indicating that weight loss, not the direct effects of GLP-1 and GIP, reduces sleep apnea, according to the report. It says Lilly's retatrutide could help test that idea.

What to watch next

Whether these retrospective signals hold up in trials that follow people over time and measure CPAP use directly.